PharmaRadar360

PharmaRadar360

🌍·15h agodiscovery

Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results

Publisher

B
Blockonomi

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Blockonomi
Region
Global
Scope
discovery
Published
September 14, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on news.google.com

Leave the platform to read the original full article on the publisher site.

Source: Blockonomi

Scope: discovery

Open original article
Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results | PharmaRadar360